Abstract
Targeted drug delivery systems using nanocarriers have emerged as a promising strategy for enhancing the therapeutic efficacy and minimizing side effects of conventional treatments. This article discusses the latest advancements in the design of nanocarriers, focusing on their potential to deliver drugs precisely to the desired sites, thus improving the pharmacokinetics and therapeutic outcomes. The paper reviews various strategies, including ligand-receptor mediated targeting, stimuli-responsive nanocarriers, and the use of multifunctional nanoparticles. Furthermore, challenges in clinical translation and future directions in nanocarrier design are also discussed.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.